Pathophysiological dynamics in the contact,coagulation,and complement systems during sepsis:Potential targets for nafamostat mesilate  

作　　者：Qiaolan He Yilin Wei Yiqi Qian Ming Zhong 

机构地区：[1]Department of Critical Care Medicine,Zhongshan Hospital,Fudan University,Shanghai,China [2]Shanghai Key Laboratory of Lung Inflammation and Injury,Shanghai,China [3]Shanghai Institute of Infectious Disease and Biosecurity,School of Public Health,Fudan University,Shanghai,China

出　　处：《Journal of Intensive Medicine》2024年第4期453-467,共15页重症医学（英文）

基　　金：supported by the National Natural Science Foundation of China(grant numbers 82102287);Key dis-cipline of Shanghai’s Three-year Action Plan to Strengthen the construction of public health system(2023-2025)(grant num-bers GWVI-11.1-14).

摘　　要：Sepsis is a life-threatening syndrome resulting from a dysregulated host response to infection.It is the primary cause of death in the intensive care unit,posing a substantial challenge to human health and medical resource allocation.The pathogenesis and pathophysiology of sepsis are complex.During its onset,pro-inflammatory and anti-inflammatory mechanisms engage in intricate interactions,possibly leading to hyperinflammation,immuno-suppression,and long-term immune disease.Of all critical outcomes,hyperinflammation is the main cause of early death among patients with sepsis.Therefore,early suppression of hyperinflammation may improve the progno-sis of these patients.Nafamostat mesilate is a serine protease inhibitor,which can inhibit the activation of the complement system,coagulation system,and contact system.In this review,we discuss the pathophysiological changes occurring in these systems during sepsis,and describe the possible targets of the serine protease inhibitor nafamostat mesilate in the treatment of this condition.

关 键 词：SEPSIS Nafamostat Contact system Coagulation system Complement system 

分 类 号：R459.7[医药卫生—急诊医学]